Multiple Myeloma News
Single Question Can Predict Treatment Discontinuation in MM Patients
Source: Myeloma - Hematology Advisor A single question can be used to predict early treatment discontinuation in patients with multiple myeloma (MM), according to research published in JAMA Network Open. Researchers found that a patient’s response to item 5 from the...
TRIM33 loss in multiple myeloma is associated with genomic instability and sensitivity to PARP inhibitors
Source: Myeloma : nature.com subject feeds Post Content Read More
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Source: Myeloma : nature.com subject feeds Post Content Read More
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
Source: Myeloma : nature.com subject feeds Post Content Read More
Like a bridge over troubled water: keeping the myeloma down en route to CAR-T
Source: Myeloma : nature.com subject feeds Post Content Read More
New, Emerging Treatment Options for Patients With Multiple Myeloma
Source: Pharmacy Times articles In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma. Read More
Model Predicts Need for Bone Marrow Sampling in Monoclonal Gammopathy of Undetermined Significance
Source: Myeloma - Hematology Advisor (HealthDay News) — A recently developed multivariable model can accurately predict smoldering multiple myeloma (SMM) or worse in persons with presumed monoclonal gammopathy of undetermined significance (MGUS), according to a study...
Carvykti Approved for Earlier Treatment of Relapsed/Refractory Multiple Myeloma
Source: Myeloma - Hematology Advisor The Food and Drug Administration (FDA) has approved Carvykti® (ciltacabtagene autoleucel) for the treatment of adults with relapsed or refractory multiple myeloma (MM) after at least 1 prior line of therapy, including a proteasome...
Novel Sequential Treatment Program Feasible in Patients With Newly Diagnosed Multiple Myeloma
Source: Myeloma - Hematology Advisor A novel sequential treatment program comprising VRD (bortezomib, lenalidomide, dexamethasone) induction, autologous stem cell transplantation (ASCT), KRD (carfilzomib, lenalidomide, dexamethasone) consolidation, and lenalidomide...
Characterization of Changes in the COST Measure of Financial Toxicity in Multiple Myeloma
Source: Myeloma - Hematology Advisor The use of the Comprehensive Score for Financial Toxicity (COST) as a tool to standardize the measurement of financial toxicity among patients with cancer is increasing, but whether changes in COST score overtime is meaningful is...